Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Mol Imaging Biol. 2017 Feb;19(1):24–30. doi: 10.1007/s11307-016-0985-2

Fig. 4.

Fig. 4

NIRF imaging demonstrates specific delivery to brain. The optical GCPII/PSMA-targeted agent YC-27 was delivered intravenously without a, b or with c, d a blocking dose of the non-fluorescent competitive agent ZJ-43. Both in situ (top) and post-transverse slice (bottom) fluorescent imaging demonstrated adequate penetration of the optical tracer to the CNS (yellow arrows), in close correlation with BBB opening as visualized by post-contrast MRI (middle, yellow arrows). Specific uptake by the brain GCPII target sites is denoted by the marked reduction of signal with ZJ-43 (Color figure online).